TipRanks
Go Ultimate55% OFF

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (6NQ) Financial Statements

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Financial Overview

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.'s market cap is currently $45.46M. The company's EPS TTM is $-0.29; its P/E ratio is -9.26; Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 42.01M$ 71.76M$ 58.61M$ 50.38M$ 41.15M
Gross Profit$ 12.99M$ 44.25M$ 35.17M$ 28.47M$ 22.67M
Operating Income$ -20.58M$ 12.43M$ 8.65M$ 9.84M$ 7.19M
EBITDA$ -7.28M$ 20.84M$ 14.89M$ 15.40M$ 13.09M
Net Income$ -19.93M$ 7.55M$ 4.76M$ 6.08M$ 4.25M
Balance Sheet
Cash & Short-Term Investments$ 1.67M$ 760.00K$ 2.17M$ 27.09M$ 19.46M
Total Assets$ 304.13M$ 298.62M$ 265.90M$ 163.10M$ 116.83M
Total Debt$ 84.65M$ 80.38M$ 70.04M$ 15.15M$ 6.49M
Net Debt$ 82.97M$ 79.62M$ 67.87M$ -11.62M$ -7.81M
Total Liabilities$ 139.39M$ 177.15M$ 153.26M$ 57.54M$ 42.27M
Stockholders' Equity$ 124.68M$ 121.47M$ 112.64M$ 105.56M$ 74.55M
Cash Flow
Free Cash Flow$ -20.81M$ -28.11M$ -117.95M$ -33.81M$ -21.71M
Operating Cash Flow$ 7.22M$ 13.73M$ -5.34M$ 2.95M$ -3.28M
Investing Cash Flow$ -27.82M$ -25.89M$ -72.90M$ -26.97M$ -4.49M
Financing Cash Flow$ 21.50M$ 10.75M$ 53.33M$ 36.82M$ 20.22M

Currency in PLN

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Earnings and Revenue History

-40M040M80M-120 %-60 %0 %60 %EarningsProfit Margin201720182019202020212022202320242025RevenueEarningsProfit Margin

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Debt to Assets

0120M240M360M30 %45 %60 %75 %LiabilitiesDebt to Assets201720182019202020212022202320242025AssetsLiabilitiesDebt to Assets

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Cash Flow

-100M-75M-50M-25M025M50M75M201720182019202020212022202320242025OperatingInvestingFinancing

Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Forecast EPS vs Actual EPS